IgE-Mediated Allergic Reactions after the First Administration of Glatiramer Acetate in Patients with Multiple SclerosisCorominas M.a · Postigo I.d · Cardona V.c · Lleonart R.a · Romero-Pinel L.b · Martinez J.d
aDivision of Allergology, Department of Internal Medicine, and bDivision of Multiple Sclerosis, Department of Neurology, Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet de Llobregat, cDivision of Allergology, Department of Internal Medicine, Hospital Universitari de la Vall d'Hebron, Institut de Recerca Vall d'Hebron, Barcelona, and dDepartment of Pharmacology, Pais Vasco University, Vitoria, Spain
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: Immediate adverse reactions to glatiramer acetate (GA), a drug used in the treatment of patients with multiple sclerosis (MS), have been poorly investigated. We studied 3 MS patients who presented adverse reactions following GA administration. Two of them experienced severe anaphylactic reactions after the first administration and the other an eyelid edema upon reintroduction 6 months after GA withdrawal. Methods: Skin prick tests (SPT) to GA and mannitol were performed on all 3 patients and in 10 atopic controls. Specific IgE (sIgE) levels to GA, myelin basic protein (MBP) and MBP fragments were assessed in all 3 patients, 6 MS patients treated with GA for more than 6 month and 10 healthy donors. Specific IgG (sIgG) to GA was also quantified in the three study groups. Both sIgE and sIgG were determined by means of the UniCAP 100 assay. Results: SPT and sIgE to GA were positive only in the 3 patients with adverse reactions while sIgE to mannitol was negative in all. sIgE tests against MBP and its fragments were negative in all individuals. Similar levels of sIgG to GA were found in all studied subjects. Conclusion: These results demonstrate the significance of sIgE in allergic reactions to GA presented by these patients and suggest the importance of strict surveillance during administration of the first GA doses.
© 2015 S. Karger AG, Basel
- Venken K, Hellings N, Liblau R, Stinissen P: Disturbed regulatory T cell homeostasis in multiple sclerosis. Trends Mol Med 2010;16:58-68.
- Racke MK, Lovett-Racke AE, Karandikar NJ: The mechanism of action of glatiramer acetate treatment in multiple sclerosis. Neurology 2010;74(suppl 1):S25-S30.
- Bayerl C, Bohland P, Jung EG: Systemic reaction to glatiramer acetate. Contact Dermatitis 2000;43:62-63.
- Rauschka H, Farina C, Sator P, Gudek S, Breier F, Schmidbauer M: Severe anaphylactic reaction to glatiramer acetate with specific IgE. Neurology 2005;64:1481-1482.
- Sander I, Kespohl S, Merget R, Goldscheid N, Degens PO, Bruning T, Raulf-Heimsoth M: A new method to bind allergens for the measurement of specific IgE antibodies. Int Arch Allergy and Immunol 2005;136:39-44.
- Rodrigo MJ, Postigo I, Wangensteen O, Guisantes JA, Martinez J: A new application of Streptavidin ImmunoCAP for measuring IgG antibodies against non-available commercial antigens. Clin Chim Acta 2010;411:1675-1678.
- Sanchez-Lopez J, Rodriguez del Rio P, Cases-Ortega B, Martinez-Cocera C, Fernandez-Rivas M: Allergy workup in immediate-type local reactions to glatiramer acetate. J Investig Allergol Clin Immunol 2010;20:521-523.
- Soriano Gomis V, Perez Sempere A, Gonzalez Delgado P, Sempere JM, Niveiro Hernandez E, Marco FM: Glatiramer acetate anaphylaxis: detection of antibodies and basophil activation test. J Investig Allergol Clin Immunol 2012;22:65-66.
- Mikol DD, Ditlow C, Usatin D, Biswas P, Kalbfleisch J, Milner A, Calenoff E: Serum IgE reactive against small myelin protein-derived peptides is increased in multiple sclerosis patients. J Neuroimmunol 2006;180:40-49.
- Smith CE, Eagar TN, Strominger JL, Miller SD: Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 2005;102:9595-9600.
- Aharoni R, Teitelbaum D, Arnon R, Sela M: Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. Proc Natl Acad Sci U S A 1999;96:634-639.
- Brenner T, Arnon R, Sela M, Abramsky O, Meiner Z, Riven-Kreitman R, Tarcik N, Teitelbaum D: Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone. J Neuroimmunol 2001;115:152-160.
- Farina C, Vargas V, Heydari N, Kumpfel T, Meinl E, Hohlfeld R: Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients. J Neuroimmunol 2002;123:188-192.
- Ponomarenko NA, Durova OM, Vorobiev II, Belogurov AA Jr, Kurkova IN, Petrenko AG, Telegin GB, Suchkov SV, Kiselev SL, Lagarkova MA, Govorun VM, Serebrykova MV, Avalle B, Tornatore P, Karavanov A, Morse HC, Thomas D, Fibroulet A, Gabibov AG: Autoantibodies to myelin basic protein catalyze site-specific degradation of their antigen. Proc Natl Acad Sci U S A 2006;103:281-286.
- Teitelbaum D, Aharoni R, Sela M, Arnon R: Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1. Proc Natl Acad Sci U S A 1991;88:9528-9532.
- Karussis D, Teitelbaum D, Sicsic C, Brenner T: Long-term treatment of multiple sclerosis with glatiramer acetate: natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy. J Neuroimmunol 2010;220:125-130.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.